RTI Biologics® Announces Launch Of BioReady™ DBM Putty
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of
orthopedic, dental, surgical specialties and other biologic implants, is
launching a new biologic implant for use in sports medicine, orthopedic
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching a new biologic implant for use in sports medicine, orthopedic and spine surgeries. BioReady™ DBM Putty and Putty with Chips is a ready-to-use, 100 percent allograft DBM solution. BioReady DBM Putty is an extension of RTI Biologics’ DBM portfolio which includes BioSet™ DBM Paste and BioAdapt™ Foam. BioReady DBM Putty is a ready-to-use demineralized bone matrix (DBM) implant that provides convenience, robust handling, verified osteoinductive* potential and sterility. It was introduced at the RTI Biologics exhibit at the North American Spine Society (NASS) annual meeting in Dallas this week. BioReady DBM Putty and Putty with Chips are 100 percent allograft, and each donor lot is tested for osteoinductive potential. Data shows that BioReady DBM Putty retains its osteoinductive potential throughout its entire shelf life. This ready-to-use implant does not require any preparation, such as thawing or mixing, and it is available in various sizes for use as a bone void filler in many types of surgical procedures. “BioReady is an exciting allograft solution that complements our portfolio of DBM implants including BioSet and BioAdapt,” said Roger Rose, executive vice president and chief commercial officer for RTI Biologics. “This ready-to-use implant addresses a significant clinical need and ensures that we maximize every gift of donation received.” RTI’s implants are sterilized through processes validated by tissue type. BioReady DBM Putty is sterilized through the Cancelle™ SP Demineralization Process. Through a combination of oxidative treatments and acid or alcohol washes, cellular debris is removed and pathogens are inactivated. Cleansing rinses remove residual chemicals, maintaining biocompatibility, and terminal low temperature, low dose gamma irradiation achieves device-level sterility, preserving the utility of the graft. BioReady DBM Putty is currently available for distribution. For further information, contact an RTI representative at (800) 624-7238.